Kenvue takeover speculation heats up ahead of M&A window

Kenvue (KVUE) is facing renewed takeover speculation as the expiration of its tax agreement with Johnson & Johnson (JNJ) in August approaches, potentially paving the way for a sale. Jefferies analysts believe Procter & Gamble (PG) is the most logical acquirer, estimating a potential all-cash deal could drive approximately 5% EPS accretion in year one and 7.5% in year two, while Unilever (ULVR) and Haleon (HLN) are also potential suitors, though with varying strategic and financial implications; Jefferies maintains a 'Buy' rating on Kenvue even without a deal, citing ongoing growth transformation and reinvestment in its brands.

Analysis

Kenvue Inc. (KVUE) is experiencing heightened takeover speculation as the August expiration of its post-spin-off tax agreement with Johnson & Johnson (JNJ) nears, potentially enabling a sale. Jefferies analysts view Kenvue's brand portfolio, which includes Tylenol, Neutrogena, Aveeno, BAND-AID, and Listerine, as attractive to suitors despite concentration (Tylenol and Neutrogena each constitute over 15% of US retail sales) and uneven performance. The presence of three activists and a recent CFO change at Kenvue are also fueling this speculation. Procter & Gamble (PG) is identified by Jefferies as the most logical acquirer, with a potential all-cash deal at a 20% premium estimated to drive approximately 5% EPS accretion in year one and 7.5% in year two, assuming $500 million in synergies; Jefferies notes P&G's presence in eight of Kenvue's top 10 categories with different product sets, minimizing antitrust risk. Unilever PLC (ULVR) is another potential suitor, though an acquisition would be a 'bigger lift,' likely requiring divestment of its food and ice cream businesses to manage debt levels, which would otherwise rise to 4.8x leverage (versus 2.7x with divestitures). A merger with Haleon PLC (HLN) is considered strategically sensible but with more modest financial benefits, offering an estimated 3% EPS accretion in year two through an 83% stock/17% cash deal; Haleon's recent divestitures like ChapStick signal potential readiness for consolidation. Independently of M&A, Jefferies maintains a 'Buy' rating on Kenvue with a $27 price target, citing its ongoing growth transformation through reinvestment in recognizable brands, with expected improvements in innovation, marketing, and tech/data investments anticipated to yield 'green shoots' in the second half of 2025. The overall market sentiment towards this news is strongly positive (sentiment score 0.65), with Kenvue specifically receiving a very high sentiment score of 0.8.

Key Decisions for Investors

• Investors in Kenvue (KVUE) should assess the dual potential for valuation uplift from an acquisition, given the approaching tax agreement expiration and multiple interested parties, alongside the company's standalone growth prospects supported by significant brand reinvestment and a $27 price target from Jefferies.
• Shareholders of Procter & Gamble (PG) might anticipate positive EPS accretion and strategic market expansion if an acquisition of Kenvue proceeds, given Jefferies' analysis of strong portfolio fit and manageable antitrust concerns.
• Investors monitoring Unilever (ULVR) and Haleon (HLN) should consider the differing complexities and financial implications of a potential Kenvue deal, including Unilever's leverage constraints necessitating divestitures and Haleon's more modest projected accretion.